 SAN FRANCISCO, March 10, 2021 GLOBE NEWSWIRE -- Olema Pharmaceuticals, Inc. Olema or Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers, today announced a poster presentation on OP-1250, a complete estrogen receptor ER antagonist CERAN and a selective ER degrader SERD being developed for the treatment of metastatic breast cancer and other womens cancers, at the American Association for Cancer Research AACR Annual Meeting to be held virtually from April 10-15, 2021. 